Psychedelic Vantage (@psychedvantage) 's Twitter Profile
Psychedelic Vantage

@psychedvantage

Venturing into the world of psychedelic drug development, research, investing, and more. Sharing insights and interviewing leading figures in the field.

ID: 1461655010958315520

linkhttps://linktr.ee/psychedelicvantage calendar_today19-11-2021 11:18:25

1,1K Tweet

964 Followers

622 Following

Matthew W. Johnson (@drug_researcher) 's Twitter Profile Photo

An extended analysis of the MDMA/PTSD rejection by the FDA. I had an insightful conversation with one of the FDA advisory panel members, Kim Witczak 💜, hosted by Rav Arora. We really dig into the nuance of the decision!

Dr. Jonathan N. Stea (@jonathanstea) 's Twitter Profile Photo

We need to stop pill-shaming. No one deserves to experience stigma towards addressing their mental health needs--whether via psychotherapy, medication, or both. Anti-psychiatry propaganda reflects poor science and mental health literacy. This is what it looks like:

Psychedelic Vantage (@psychedvantage) 's Twitter Profile Photo

Psilera receives positive preclinical in vivo data for frontotemporal dementia (FTD) candidate, PSIL-006 prnewswire.com/news-releases/…

Psychedelic Vantage (@psychedvantage) 's Twitter Profile Photo

Cybin Announces Results of Annual and Special Meeting of Shareholders and Share Consolidation $CYBN businesswire.com/news/home/2024…

MAPS (@maps) 's Twitter Profile Photo

International Overdose Awareness Day is a time to remember the lives we've lost to overdose and reflect on how we can prevent more tragedies. In honor of this day, MAPS is teaming up with @SSDPofficial to share essential harm reduction tips that could make all the difference.

Beckley Psytech (@beckleypsytech) 's Twitter Profile Photo

Results from our Phase I study of BPL-003 in healthy volunteers have now been published in Volume 38, Issue 8 of the Journal of Psychopharmacology, showing BPL-003 can produce a rapid onset and short duration of subjective effect. Find the full paper here: journals.sagepub.com/doi/10.1177/02…

Psychedelic Vantage (@psychedvantage) 's Twitter Profile Photo

GH Research Announces Appointment of Dr. Velichka “Villy” Valcheva to Chief Executive Officer $GHRS globenewswire.com/news-release/2…

Psychedelic Vantage (@psychedvantage) 's Twitter Profile Photo

GH Research Reports Second Quarter 2024 Financial Results and Provides Business Updates $GHRS globenewswire.com/news-release/2…

Psychedelic Vantage (@psychedvantage) 's Twitter Profile Photo

Psychedelic compounds in clinical development that may be able to fit into the 2 hour in-clinic treatment paradigm used in 3,500+ clinics in the U.S. - Cybin’s CYB004 (deuterated N,N-DMT) -Beckley Psytech’s BPL-003 (intranasal transmucosal formulation of 5-MeO-DMT) and ELE-101